Canada markets closed

Mesoblast Limited (MEOBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6750-0.1150 (-14.56%)
At close: 02:05PM EDT

Mesoblast Limited

55 Collins Street
Level 38
Melbourne, VIC 3000
61 3 9639 6036

Full Time Employees83

Key Executives

NameTitlePayExercisedYear Born
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director753.23kN/A1957
Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director637.73kN/A1951
Mr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerN/AN/AN/A
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)General Counsel & Corporate ExecutiveN/AN/A1968
Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersN/AN/AN/A
Mr. Michael Schuster BSc, M.B.A., MSHead of Pharma PartneringN/AN/A1977
Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality ManagementN/AN/AN/A
Mr. Justin Horst B.S.Head of ManufacturingN/AN/AN/A
Ms. Niva Sivakumar B.Com., L.L.B.Joint Company SecretaryN/AN/AN/A
Mr. Paul Hughes BPHARMJoint Company SecretaryN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Corporate Governance

Mesoblast Limited’s ISS Governance QualityScore as of May 1, 2024 is 6. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.